Virginia Commonwealth University
Richmond, Virginia, 23298, United States
NCT Number: NCT03829683
The purpose of this research study is to test the safety, tolerability, and effectiveness of Vitamin C (ascorbic acid) intravenous infusion when used to treat alcoholic hepatitis (inflammation of the liver from heavy alcohol use) and sepsis (life-threatening complication of an infection).
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Richmond, Virginia, 23298, United States
Alcoholic hepatitis is inflammation of the liver due to alcohol consumption. It can cause one or more of the following symptoms such as jaundice (yellow discoloration of the eyes and skin), pain on the right side of the abdomen, and is accompanied by an enlarged liver. Sepsis is a life-threatening complication of an infection. As the body tries to fight an infection it sends chemicals into the bloodstream. These chemicals that are trying to fight the infection can cause inflammation. This inflammation can cause damage to many body systems and make them fail. Patients with alcoholic hepatitis and sepsis have low levels of Vitamin C in the bloodstream. Vitamin C has been shown to reduce inflammation and organ dysfunction in patients with severe infections.
The investigators do not yet know if Vitamin C will be effective in alcoholic hepatitis. Taking Vitamin C by mouth is not effective as a treatment in people with this condition so participants will receive the Vitamin C intravenously (IV). Participants will be randomly assigned to receive either Vitamin C or a placebo given through an IV every six hours for four days.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
200mg/kg/24hours
Other names: ascorbic acid, AscA, Ascor
50mL intravenously every 6 hours
Other names: D5W
Time frame: Baseline and 96 hours
Change in MELD score from Day 0 to Day 4. MELD score ranges from 6 (least sick) to 40 (most sick) based on blood tests which ranks the degree of sickness from liver disease. The lab tests used to determine the MELD score are creatinine, bilirubin, and international normalized ratio (INR).
Time frame: Baseline and 96 hours
A number that ranges from 0 (least sick) to 24 (most sick) and ranks the degree of sickness from liver failure and several other organ systems in a critically ill person. The score is determined by evaluating a person's liver function, kidney function, nervous system (brain), coagulation (blood clotting), circulation (blood pressure), and respiratory status (breathing)
Time frame: Baseline and 96 hours
Standard blood test used to determine the severity and nature of liver problems.
Time frame: Baseline and 96 hours
Standard blood test used to determine the severity and nature of liver problems.
Time frame: Baseline and 96 hours
Standard blood test used to determine the severity and nature of liver problems.
Time frame: Baseline and 96 hours
Standard blood test used to determine the severity and nature of liver problems.
Time frame: Baseline and 96 hours
Standard blood test used to determine the severity and nature of liver problems.
Time frame: up to 96 hours
Observation about the need to change the dose of study medication and symptoms such as headache, dizziness, dry mouth, nausea, vomiting, flushing, rash, or hypotension (low blood pressure)
Time frame: Baseline and 96 hours
An electrocardiogram (ECG or test of the electrical activity of the heart) is performed to determine if there are changes to the heart rhythm.
Time frame: Baseline and 96 hours
Urine samples are collected to determine changes in pH (acidity) that could indicate a risk for kidney stones. The pH scale ranges from 0 to 14, with smaller numbers meaning more acidic and higher numbers meaning more basic. A pH of 7 is considered to be neutral. Normal levels of urine pH range from 4.6 - 8 on the pH scale.
Time frame: Baseline and 96 hours
Urine samples are collected to check for the presence of crystalluria (microscopic crystals) that could indicate a risk for kidney stones.
Time frame: up to 168 hours
Documentation of the need for more intensive medical care such as ventilator (breathing machine) or vasopressors (intravenous medications use increase blood pressure) when not needed at baseline
Time frame: Day 28
The number of days not spent in an intensive care unit (ICU)
Time frame: Day 28
Any cause of death that is anticipated or unanticipated
Time frame: Day 90
Any cause of death that is anticipated or unanticipated
Time frame: Day 90
The number of days spent outside of the hospital
Virginia Commonwealth University
Other
Acronym: CITRIS-AH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02344680
Acquired Immunodeficiency Syndrome, Adenocarcinoma
Lusaka, Lusaka Province, Zambia
View Trial DetailsNCT03158818
Adenocarcinoma, Alcohol-Induced Disorders
Lusaka, Zambia
View Trial DetailsNCT05594953
Acute Liver Failure, Alcohol-Induced Disorders
Dallas, Texas, United States
View Trial DetailsNCT03149627
Alcohol-Induced Disorders, Alcohol-Related Disorders
Lusaka, Zambia
View Trial Details